Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOncoHost Ltd.
About this trial
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment.
Patients will provide biological samples before and during their treatment, and clinical data will be collected.
Eligibility criteria
Qualifiers
Provision of informed consent prior to any study-specific procedures.
Male or female aged at least 18 years.
ECOG PS - 0/1-2.
Disqualifiers
Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment.
Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.
Trial design
Treatments tested in this trial
- blood, stool and tissue samples collection
Treatment groups
350 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov